Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|BRAF V600E||colorectal cancer||no benefit||Vemurafenib||Preclinical - Cell line xenograft||Actionable||In a preclinical study, colorectal cancer cell lines were not sensitive to growth inhibition by Zelboraf (vemurafenib) in culture or xenograft models, due to feedback activation of EGFR signaling (PMID: 22281684).||22281684|
|BRAF V600E||colorectal cancer||no benefit||Vemurafenib||Phase II||Actionable||In a Phase II trial, Zelboraf (vemurafenib) did not demonstrate meaningful clinical activity as a single agent, resulted in partial response in 5% (1/21) and stable disease in 33% (7/21) of patients with metastatic colorectal cancer harboring BRAF V600E (PMID: 26460303; NCT00405587).||26460303|
|BRAF V600E||colorectal cancer||no benefit||Vemurafenib||Preclinical - Cell culture||Actionable||In a preclinical study, colorectal cancer cell lines harboring BRAF V600E demonstrated decreased response to Zelboraf (vemurafenib) in culture (PMID: 27312529).||27312529|
|PubMed Id||Reference Title||Details|
|(27312529)||Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.||Full reference...|
|(26460303)||Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.||Full reference...|
|(22281684)||Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.||Full reference...|